Few & Far Between: Conversations from the Front Lines of Drug Development

Chris O'Brien
  • ٥٫٠ (١٣)
  • علوم حياة
  • يتم التحديث شهريًا

Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for Conversations from the Front Lines of Drug Development - from clinical research and policymakers to biotech innovators and industry leaders.

  1. ٣ سبتمبر

    Episode 59, Part One: Yochi Slonim, Co-Founder and CEO at Anima Biotech

    What do software bugs and human cells have in common? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Tune in to part one of this special two-part episode as we double-click on #AIagents, building neural networks, and syncing visual biology with real-world biology. Okay, let's start the podcast!

    ٤٤ من الدقائق

  2. ١٤ أغسطس

    Episode 58: Jerry McLaughlin, CEO and Board Member at Life Biosciences

    How does a biopharma background prepare you for the biotech playground? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jerry McLaughlin, CEO and Board Member at Life Biosciences, for an insightful discussion on cellular rejuvenation, working hand in hand with a board of directors, and knowing when to walk away from a clinical trial. Tune in today!

    ٤٥ من الدقائق

  3. ٢٢ يوليو

    Episode 57: Jim Brown, DVM, President and CEO of DURECT Corporation

    Is the epigenome the "software" of the cell nucleus? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jim Brown, President and CEO of DURECT Corporation, for a conversation on the importance of a pharmacoeconomic strategy, developing new treatments for alcohol associated hepatitis, and moving beyond what a single individual can do in clinical research. Tune in today!

    ٤٥ من الدقائق

  4. ١٥ يوليو

    Episode 56, Part Two: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics

    How do experienced troubleshooters solve a difficult problem? By asking the right questions first! Welcome back to part two of our conversation with Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics. Join host Chris O'Brien as he and Dr. Tolentino, explore the traits of top problem solvers, the power of communication, and how silos and "bad apples" can undermine today's biotechs. Okay, let's start the podcast!

    ٣٩ من الدقائق

  5. ٩ يوليو

    Episode 55: Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®

    How much do you know about clinical trials in Latin America? Take a deep dive with us as we explore the benefits and risks of running studies in this region. In our latest episode of the Biorasi Few & Far Between podcast, host Chris O'Brien welcomes Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®. Tune in as we spotlight the advantages of running studies in #LATAM - from data quality to speed to approval.

    ٣٩ من الدقائق

  6. ٢٨ مايو

    Episode 54, Part One: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics

    The challenge? Decoding the human immune system. Get ready to meet the top challenger on today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics, to the podcast. Tune in to part one of this special two-part episode as we explore Michael's start in ophthalmology, groundbreaking treatments in intra-retinal therapy, and the importance of being a great communicator. Okay, let's start the podcast!

    ٤٥ من الدقائق

  7. ٢٩ أبريل

    Episode 53: Frank David, Founder and Managing Director, Pharmagellan

    How do mission, vision, and data analysis fit into today's biotech goals? Host Chris O'Brien welcomes Frank David, Founder and Managing Director of Pharmagellan to the podcast. Tune in as we explore R&D strategy, de-risking tactics, and how to think about valuation. Listen in to the latest episode of the Biorasi Few & Far Between podcast today!

    ٥١ من الدقائق

  8. ٢٣ أبريل

    Episode 52: Joshua Kresh, Emily Michiko Morris, and Mark Schultz, IPPI

    How does a biotech balance great science with IP security to tell their story? Find out on today's episode of the Few & Far Between podcast! Host Chris O'Brien welcomes Joshua Kresh, Emily Michiko Morris, and Mark Schultz from IPPI: The Intellectual Property Policy Institute. Tune in for a fascinating discussion on the dos and don'ts of IP protection. Listen to the latest episode today!

    ٥٢ من الدقائق
مشاهدة الكل (٣٥)

٥
من ٥
‫١٣ من التقييمات‬

حول

Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for Conversations from the Front Lines of Drug Development - from clinical research and policymakers to biotech innovators and industry leaders.

المعلومات

قد يعجبك أيضًا